Sevoflurane vs. propofol for general Anesthesia in patients with acute ischemic stroke treated with endoVascular treatmEnt (SAVE trial)

2025-523709-13-00 · tracked via the Priya Life Science EU tracker

Sponsor

Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

Sponsor type

Hospital/Clinic/Other health care facility

Therapeutic area

Anesthesia and Analgesia

Decision date

07/04/2026

Enrollment target

330

Sites

Spain

Condition studied

Acute ischemic stroke

Investigational medicinal product(s)

Sevoflurano Baxter 100% líquido para inhalación del vapor EFGPropofol Fresenius 20 mg/ml emulsión inyectable y para perfusión EFG

Eligibility

Age group

18-64 years, 65+ years

Sex

Female, Male

Primary endpoint

The primary outcome of the study will be the final infarct volume (FIV), assessed by Fluid-Attenuated Inversion Recovery (FLAIR) sequence on magnetic resonance imaging (MRI) follow-up at 72 hours post-treatment ± 24 hours.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523709-13-00 on CTIS ↗ ← All trials in the EU